Terms ending in 2032
Every in-force patent on Kymab Limited's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,253,965 | Animal Models and Therapeutic Molecules In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,445,581 | Animal Models and Therapeutic Molecules In force · High confidence | Kymab Limited | In force | High confidence | |
| US 9,896,516 | Animal Models and Therapeutic Molecules In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,251,377 | Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 10,774,155 | Animal Models and Therapeutic Molecules In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,297,811 | Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies In force · High confidence | Kymab Limited | In force | High confidence | |
| US 11,051,497 | Manipulation of Immunoglobulin Gene Diversity and Multi-Antibody Therapeutics In force · High confidence | Kymab Limited | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.